Acadia Healthcare (NASDAQ:ACHC) Posts Quarterly Earnings Results, Beats Expectations By $0.12 EPS

Key Points

• Acadia Healthcare reported earnings of $0.83 EPS for the quarter, exceeding the consensus estimate of $0.70 by $0.13.
• The company's stock price increased by 1.8% mid-day following the earnings announcement, trading at $21.76.
• Acadia Healthcare updated its fiscal year 2025 guidance to a range of $2.450-2.65 EPS amidst varying analyst ratings and price target adjustments.

Acadia Healthcare (NASDAQ:ACHC - Get Free Report) released its quarterly earnings data on Tuesday. The company reported $0.83 EPS for the quarter, beating the consensus estimate of $0.71 by $0.12, Zacks reports. Acadia Healthcare had a return on equity of 8.72% and a net margin of 5.94%. The firm's quarterly revenue was up 9.2% on a year-over-year basis. During the same period last year, the firm earned $0.91 EPS. Acadia Healthcare updated its FY 2025 guidance to 2.450-2.65 EPS.

Acadia Healthcare Stock Performance

NASDAQ:ACHC traded up $0.39 during midday trading on Tuesday, reaching $21.76. The stock had a trading volume of 3,366,743 shares, compared to its average volume of 2,148,767. The company has a debt-to-equity ratio of 0.72, a current ratio of 1.35 and a quick ratio of 1.35. The firm's fifty day simple moving average is $22.47 and its 200-day simple moving average is $28.34. The stock has a market capitalization of $2.00 billion, a P/E ratio of 10.72, a PEG ratio of 4.02 and a beta of 0.88. Acadia Healthcare has a 1-year low of $20.35 and a 1-year high of $82.40.

Institutional Investors Weigh In On Acadia Healthcare

Several hedge funds have recently modified their holdings of ACHC. Goldman Sachs Group Inc. raised its position in Acadia Healthcare by 21.1% in the first quarter. Goldman Sachs Group Inc. now owns 698,225 shares of the company's stock worth $21,170,000 after purchasing an additional 121,444 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its holdings in Acadia Healthcare by 8.7% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 340,916 shares of the company's stock worth $10,337,000 after buying an additional 27,207 shares in the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new position in shares of Acadia Healthcare during the first quarter valued at $1,600,000.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on the company. Guggenheim started coverage on Acadia Healthcare in a research note on Wednesday, April 9th. They set a "buy" rating and a $36.00 price objective on the stock. Mizuho cut their price target on Acadia Healthcare from $37.00 to $32.00 and set a "neutral" rating on the stock in a report on Wednesday, May 14th. KeyCorp decreased their price objective on Acadia Healthcare from $65.00 to $55.00 and set an "overweight" rating for the company in a report on Wednesday, May 14th. Barclays reduced their price target on Acadia Healthcare from $35.00 to $28.00 and set an "equal weight" rating for the company in a research report on Wednesday, May 14th. Finally, Wall Street Zen raised shares of Acadia Healthcare from a "sell" rating to a "hold" rating in a research note on Sunday. Five research analysts have rated the stock with a hold rating and six have given a buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $47.94.

Acadia Healthcare Company Profile

Acadia Healthcare Company, Inc provides behavioral healthcare services in the United States and Puerto Rico. The company develops and operates acute inpatient psychiatric facilities, specialty treatment facilities comprising residential recovery facilities and eating disorder facilities, comprehensive treatment centers, and residential treatment centers, as well as facilities offering outpatient behavioral healthcare services for the behavioral healthcare and recovery needs of communities.